Key Clinical Message Ibrutinib, an inhibitor of the Bruton’s tyrosine kinase of the B‐cell receptor pathway, is an effective therapeutic agent for B‐cell lymphomas. As these drugs are novel, long‐term or rare adverse events are not yet known. We report the first case of ibrutinib‐induced severe liver injury in a patient with relapsed/refractory CLL.
All Keywords
【저자키워드】 chronic lymphocytic leukemia, Liver injury, Ibrutinib, tyrosine kinase inhibitors, Richter's syndrome,
【저자키워드】 chronic lymphocytic leukemia, Liver injury, Ibrutinib, tyrosine kinase inhibitors, Richter's syndrome,